By Ryan Davis ( June 24, 2009, 12:00 AM EDT) -- In response to Federal Trade Commission Chairman Jon Leibowitz's claims that banning "pay-for-delay" patent settlements between generics and branded drugmakers would save consumers $3.5 billion a year, leading generics maker Teva Pharmaceuticals USA decried the supposed savings as based on a "flawed assumption."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.